296
Participants
Start Date
December 31, 2012
Primary Completion Date
September 30, 2016
Study Completion Date
February 7, 2017
Icotinib
Icotinib: 125 mg is administered orally three times per day.
Chemotherapy
First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
Chinese People's Liberation Army (PLA) General Hospital, Beijing
Beijing Hospital for Chest Tumors & Tuberculosis Diseases, Beijing
Harbin Medical Univercity Cancer Hospital, Harbin
The First Hospital of China Medical University, Shenyang
The First Bethune Hospital of Jilin Univercity, Changchun
Shanghai Chest Hospital Affiliated to Shanghai Jiaotong Univercity, Shanghai
Zhongshan Hospital Affiliated to Fudan Univercity, Shanghai
Changhai Hospital, The Second Military Medical University, Shanghai
Jiangsu Cancer Hospital, Nanjing
Jiangsu Provincal Tumor Hospital, Nanjing
The First Affiliated Hospital of Anhui Medical Univercity, Hefei
Shandong Cancer Hospital, Jinan
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Xinqiao Hospital, The Third Military Medical University, Chongqing
Henan Provincal Tumor Hospital, Zhengzhou
The First Affiliated Hospital Of Guangzhou Medical Collage, Guangzhou
Nanfang Hospital, Southern Medical University, Guangzhou
Sichuan Provincal Tumor Hospital, Chengdu
West China Hospital, Sichuan University, Chengdu
Xijing Hospital, Xian
Hebei Provincal Tumor Hospital, Shijiazhuang
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
INDUSTRY